- Home
- VNRX
VNRX
VolitionRX Limited
as 11-15-2024 4:00pm EST
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HENDERSON |
| Market Cap: | 67.2M | IPO Year: | N/A |
| Target Price: | $4.17 | AVG Volume (30 days): | 135.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.43 - $1.23 | Next Earning Date: | 11-14-2024 |
| Revenue: | $1,285,827 | Revenue Growth: | 88.32% |
| Revenue Growth (this year): | 180.66% | Revenue Growth (next year): | 558.69% |
Stock Insider Trading Activity of VolitionRX Limited (VNRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Innes Guy Archibald | VNRX | Director | Aug 20 '24 | Buy | $0.67 | 150,000 | $100,500.00 | 406,683 |
Latest VolitionRX Limited News
VNRX Breaking Stock News: Dive into VNRX Ticker-Specific Updates for Smart Investing
GuruFocus.com
a day ago
VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Associated Press Finance
2 days ago
VolitionRX: Q3 Earnings Snapshot
PR Newswire
3 days ago
VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update
GuruFocus.com
3 days ago
VolitionRX Ltd (VNRX) Q3 2024 Earnings Report Preview: What to Look For
PR Newswire
9 days ago
VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
PR Newswire
11 days ago
Volition Appoints Timothy I. Still as Chairman
PR Newswire
17 days ago
Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating
PR Newswire
a month ago
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar
Compare VNRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VNRX VolitionRX Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.